Research compound supplied in Australia by Pulse Biolabs for laboratory use. Available in 10mg, 40mg.
MOTS-c is a small peptide encoded by the DNA inside mitochondria rather than by the cell nucleus. It is studied as a signal cells use when their energy supply comes under stress.
MOTS-c is a 16-amino-acid peptide encoded by mitochondrial DNA rather than the cell nucleus. It is studied as a signal mitochondria may send to the rest of the cell when energy is scarce, including movement into the nucleus to alter stress-response genes. Evidence comes from cell culture and mouse studies of administered peptide, plus measurements of the naturally occurring peptide in small groups of adults; no randomised trial of administered MOTS-c in people was identified.
Read the full research note →| Presentation | Code | Status | Price |
|---|---|---|---|
| 10mg | MC10 | In stock | $70 |
| 40mg | MC40 | In stock | $200 |
1 published report for MOTS-C, listed by presentation and batch. Where a batch reference is shown, match it to the batch on the vial label; a report for an earlier batch is historical documentation and does not describe the batch currently supplied. Where no batch reference is published, the report cannot be matched to a vial and is historical documentation only. No report is published for 40mg. Each report describes the sample and the tests shown on it. A purity result does not by itself establish identity, quantity, sterility or endotoxin status unless those tests appear on the report, and a report for one batch does not describe another.
| Presentation | Report | Batch | |
|---|---|---|---|
| 10mg | manufacturer certificate | B.3.26 | Open |
Supplied as lyophilised (freeze-dried) powder in a sealed vial. Store sealed and protected from light at the conditions stated on the product label or supplied specification. Solvent choice, concentration and handling after reconstitution depend on the compound and on the laboratory’s own procedures, and are not specified here.
MOTS-c is not an approved medicine in Australia. No regulator-approved MOTS-c medicine was identified in any jurisdiction for this note.
Status checked 2026-09-23. Details and sources in the research note.